GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...

The announcement of a 15% tariff on pharmaceutical imports to the U.S. from the European Union may have not been the ideal ...

As pharmaceutical import tariffs take shape in Europe, President Donald Trump is rounding out the week by spotlighting ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

A stellar launch of the rare heart disease med Amvuttra has boosted Alnylam’s market cap above $50 billion. | A stellar launch of Amvuttra in the rare heart disease ATTR-CM has boosted Alnylam’s ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...